Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211.SZ)
- Previous Close
16.23 - Open
16.40 - Bid 15.89 x --
- Ask 15.90 x --
- Day's Range
15.60 - 16.11 - 52 Week Range
13.60 - 25.77 - Volume
3,041,857 - Avg. Volume
4,693,936 - Market Cap (intraday)
4.602B - Beta (5Y Monthly) --
- PE Ratio (TTM)
49.69 - EPS (TTM)
0.32 - Earnings Date --
- Forward Dividend & Yield 0.48 (2.96%)
- Ex-Dividend Date May 27, 2024
- 1y Target Est
--
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. The company provides APIs and intermediates, and formulations; and dimethyl ether gas and a-chloropropionyl chloride chemical products. It is also involved in the contract research, manufacture, and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc. The company was founded in 1995 and is based in Jingmen, China.
www.biocause.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 301211.SZ
View MorePerformance Overview: 301211.SZ
Trailing total returns as of 4/28/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 301211.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 301211.SZ
View MoreValuation Measures
Market Cap
4.67B
Enterprise Value
3.04B
Trailing P/E
50.72
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.41
Price/Book (mrq)
2.02
Enterprise Value/Revenue
6.82
Enterprise Value/EBITDA
24.12
Financial Highlights
Profitability and Income Statement
Profit Margin
20.53%
Return on Assets (ttm)
0.80%
Return on Equity (ttm)
3.92%
Revenue (ttm)
445.86M
Net Income Avi to Common (ttm)
91.55M
Diluted EPS (ttm)
0.32
Balance Sheet and Cash Flow
Total Cash (mrq)
1.64B
Total Debt/Equity (mrq)
0.23%
Levered Free Cash Flow (ttm)
-92.19M